ClinicalTrials.gg
CompletedNCT03002974anaGOUpdated Jul 15, 2020Results posted

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis

A Phase 2 interventional study of Anakinra 100 mg and Triamcinolone Acetonide 40 mg in Acute Gouty Arthritis, sponsored by Swedish Orphan Biovitrum. Completed at 37 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-15.

Sponsored by Swedish Orphan Biovitrum · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 164 studies in Gout with a site in United States — 12 open to participants now, 16 under way, 3 of them phase 3. Gout · United States.

Enrollment
51st of 149
165 · median 74
Started
2016
with 1 other
Phase 2
45 of 164
2 open now
Registered
87th of 164
by date

Among the 164 studies in Gout with a site in United States, this one is the 51st largest by enrollment of the 149 interventional ones that give a count, is one of 2 that started in 2016, is one of 45 in phase 2, and was the 87th registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

12 of the 164 studies in Gout with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Gout with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate how anakinra relieves pain for patients with acute gout that cannot take non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine. The patients will be divided in different treatment groups to compare anakinra to the available drug triamcinolone.

Read the detailed description

Patients will be randomized to treatment at their first gout flare in the study. The first treatment period will be followed by an extension period during which the patients will receive the same treatment for any subsequent flares within 52 weeks of randomization of last patient in the study. The extension period for the individual patient in the study will be maximum two years (104 weeks). Each new flare treated will initiate a new series of study visits and assessments according to specified schedule of events. Only if a patient experience a new flare after Day 15 of the latest flare they can start a new treatment period. The comparison of primary interest is between anakinra (100 mg and 200 mg combined) and 40 mg triamcinolone, and as a secondary objective the 2 different doses of anakinra will be evaluated as well as assessment for subsequent flares.

03

Conditions studied

  • Acute Gouty Arthritis

Browse trials for

Keywords

  • Gout
  • Interleukin 1 receptor antagonist
  • IL-1 receptor antagonist
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Patient meeting the American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) 2015 gout classification criteria
  • History of ≥1 self-reported flares of gouty arthritis within 12 months
  • Current ongoing flare of gouty arthritis characterized by pain intensity
  • Currently tender and swollen joint
  • Onset of current flare within 4 days
  • Intolerant, unresponsive, or not appropriate for treatment with NSAIDs and colchicine (both treatment options)
  • If on urate-lowering therapy, on a stable dose and regimen
  • Women of willing to use adequate

Inclusion criteria for treatment of subsequent flare(s)

  • Current flare of gouty arthritis characterized by pain intensity
  • Currently tender and swollen joint
  • Women of childbearing potential willing to use adequate contraception

Exclusion criteria

Exclusion Criteria:

  • Use of specified pain relief medications or biologics (including , narcotics, paracetamol/acetaminophen, NSAIDs, colchicine, IL-blockers and tumor necrosis factor inhibitors) within specified periods prior to randomization
  • to triamcinolone
  • Polyarticular gouty arthritis involving more than 4 joints
  • Rheumatoid arthritis, evidence/suspicion of infectious/septic arthritis, or other acute inflammatory arthritis
  • History of within the past 5 years. Exceptions are basal cell skin cancer, carcinoma-in-situ of the cervix or low-risk prostate cancer after curative therapy.
  • Known to Escherichia coli-derived proteins, Kineret® (anakinra), Kenalog® (triamcinolone acetonide) or any components of the products.
  • Known presence or suspicion of active or recurrent bacterial, fungal or viral infections, including tuberculosis, or infection or or C infection
  • Presence of severe renal function impairment chronic kidney disease (CKD) stages 4 and 5
  • Presence of neutropenia
  • Uncontrolled hematologic, pulmonary, endocrine, metabolic, gastrointestinal, central nervous system or hepatic disease
  • History of myocardial infarction, unstable angina, cerebrovascular events, or coronary artery bypass grafting, (NYHA) class III or IV heart failure within the previous 3 months
  • Patients who have undergone major surgery within 2 weeks, or have an unhealed operation wound/s
  • Presence of any medical or psychological condition or laboratory result that in the opinion of the investigator might create risk to the patients or to the study.
  • Earlier or current treatment with anakinra
  • Pregnant or lactating women
  • History of >12 flares overall in the 6 months prior to randomization

Exclusion criteria for treatment of subsequent flare(s):

  • Known presence or suspicion of active or recurrent bacterial, fungal or viral infections, including tuberculosis, or HIV infection or hepatitis B or C infection.
  • Presence of severe renal function impairment CKD stages 4 and 5
  • Presence of neutropenia
  • History of myocardial infarction, unstable angina, cerebrovascular events, or coronary artery bypass grafting, NYHA class III or IV heart failure within the previous 3 months
  • Patients who have undergone major surgery within 2 weeks or have an unhealed operation wound/s.
  • Pregnant or lactating women.
  • Presence of any condition or laboratory result that in the opinion of the investigator makes the patient not appropriate for treatment
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    Anakinra 100 mg

    1 subcutaneous injection of Anakinra 100 mg once daily for 5 days, 1 subcutaneous injection of Placebo to Anakinra 100 mg once daily for 5 days and 1 single intramuscular injection of Placebo to Triamcinolone Acetonide 40 mg

    Drug: Anakinra 100 mg · Drug: Placebo to Anakinra 100 mg · Drug: Placebo to Triamcinolone Acetonide 40 mg

  • Experimental
    Anakinra 200 mg

    2 subcutaneous injections of Anakinra 100 mg (2 syringes) once daily for 5 days and 1 single intramuscular injection of Placebo to Triamcinolone Acetonide 40 mg

    Drug: Anakinra 100 mg · Drug: Placebo to Triamcinolone Acetonide 40 mg

  • Active comparator
    Triamcinolone 40 mg

    2 subcutaneous injections of Placebo to Anakinra 100 mg once daily for 5 days and 1 single intramuscular injection of Triamcinolone Acetonide 40 mg

    Drug: Triamcinolone Acetonide 40 mg · Drug: Placebo to Anakinra 100 mg

Interventions

  • 100 mg/0.67 mL solution in single-use prefilled syringes for subcutaneous injection

    Also known as: Kineret

  • 1 mL intramuscular injection of a 40 mg/mL injectable suspension

    Also known as: Kenalog, Triamcinolone

  • DrugPlacebo to Anakinra 100 mg

    sterile solution for injection (0.67 mL) in a single-use prefilled syringe identical to the anakinra syringe

    Also known as: Placebo Kineret

  • DrugPlacebo to Triamcinolone Acetonide 40 mg

    1 mL intramuscular injectable suspension with identical appearance as the Triamcinolone Acetonide suspension

    Also known as: Placebo Kenalog

06

What researchers measure

Primary outcomes

  1. Change in Patient-assessed Pain Intensity in the Index Joint From Baseline to 24-72 Hours for the First Gout Flare Treated in the Study as Measured by VAS

    Patients will score their pain intensity in the joint most affected at baseline (index joint) on a 0-100 mm visual analogue scale (VAS), ranging from no pain (0) to unbearable pain (100). Average of the assessments performed at 24, 48 and 72 hours.

    Time frame: At baseline (pre-dose) and at 24, 48 and 72 hours for the first gout flare treated in the study

Secondary outcomes

  1. Change in Patient-assessed Pain Intensity in the Index Joint From Baseline at Time Points From 6 Hours to 8 Days for the First Gout Flare Treated in the Study as Measured by 5-point Likert Scale

    Patients will score their pain intensity in the joint most affected at baseline (index joint) on a 5-point Likert scale (0-4 point scale: "none", "mild", "moderate", "severe", "extreme") at time points baseline (pre-dose) and at 6, 12, 18, 24, 36, 48 and 72 hours and Day 5, 6, 7 and 8.

    Time frame: At baseline (pre-dose) and at 6, 12, 18, 24, 36, 48 and 72 hours and Day 5, 6, 7 and 8 for the first gout flare treated in the study

  2. Median Time to Onset of Effect

    Onset of effect defined as 20% change from baseline pain intensity in the index joint on a visual analogue scale (VAS)

    Time frame: From baseline (predose) up to Day15 of the first flare treated in the study

  3. Median Time to Response

    Response defined as 50% change from baseline pain intensity on a visual analogue scale (VAS)

    Time frame: From baseline (predose) up to Day15 of the first flare treated in the study

  4. Median Time to Resolution of Pain

    Resolution of pain defined as \<10 mm on VAS, a continuous 0 to 100 mm visual analogue scale, ranging from no pain (0) to unbearable pain (100), in the index joint

    Time frame: From baseline (predose) up to Day15 of the first flare

  5. Median Time to First Intake of Rescue Medication From First Investigational Drug Administration

    Time to first intake of rescue medication for acute gout, measured in hours from first investigational drug administration

    Time frame: From Day 1 to Day 15 for the first flare treated

  6. Physician's Assessment of Global Response to Treatment

    5-point Likert scale (0- to 4-point scale: "none", "mild", "moderate", "severe, "extreme") where higher score mean worse outcome

    Time frame: At 72 hours, Day 8 and Day 15 for the first flare treated in the study

  7. Physician's Assessment of Clinical Signs in Index Joint: Tenderness

    4-point Likert scale (0=no pain, 1= mild/patient states there is pain when touched, 2= moderate/patient states there is pain and Winces, 3=severe/patient states there is pain, winces and withdraws

    Time frame: at 72 hours, Day 8 and Day 15 for the first flare treated in the study

  8. Physician's Assessment of Clinical Signs in Index Joint: Swelling

    4-point Likert scale (0=no swelling, 1= mild swelling, 2=moderate swelling, 3=severe swelling or bulging beyond joint margins)

    Time frame: at 72 hours, Day 8 and Day 15 for the first flare treated in the study

  9. Physician's Assessment of Clinical Signs in Index Joint: Erythema

    Physicians assessment of clinical signs with 2 outcomes: Absent=no erythema, present=erythema

    Time frame: at 72 hours, Day 8 and Day 15 for the first flare treated in the study

  10. Patient´s Assessment of Global Response to Treatment (5-point Likert Scale)

    5-point Likert scale (0- to 4-point scale: 0=excellent, 1=very good, 2=good, 3=fair, 4=poor response to treatment) where lower rate indicates better response to treatment

    Time frame: at 72 hours, Day 8 and Day 15 for the first flare treated in the study

  11. Change From Baseline in the Inflammatory Biomarker C Reactive Protein

    This endpoint represents the change from baseline, mg/dL, of the inflammatory biomarker C reactive protein

    Time frame: baseline (predose) and at 72 hours, Day 8 and Day 15 for the first flare treated in the study

  12. Change From Baseline in the Inflammatory Biomarker Serum Amyloid A

    This endpoint represents the change from baseline, mg/L, of the inflammatory biomarker Serum amyloid A

    Time frame: baseline (predose) and at 72 hours, Day 8 and Day 15 for the first flare treated in the study

  13. The Percent of Patients With at Least One Adverse Event

    All adverse events to be recorded Day 1 - Day 28 for each flare. Serious adverse events (SAE) will be collected from informed consent until week 12 for each flare. Any SAE with suspected causal relationship should be reported irrespective of the time of occurrence.

    Time frame: Through study completion, at 12 weeks after last flare treated during the extension period

  14. The Percent of Patients With at Least One Serious Adverse Event, Including Death

    Serious Adverse Events (SAE) will be collected from informed consent until week 12 for each flare. Any SAE with suspected causal relationship should be reported irrespective of the time of occurrence.

    Time frame: Through study completion, at 12 weeks after last flare treated during the extension period

  15. Serum Concentration of Endogenous Interleukin-1 Receptor Antagonist /Anakinra

    This endpoint represents the level of of endogenous interleukin-1 receptor antagonist /anakinra

    Time frame: Baseline (predose) and at 72 hours, Day 8, Day 15, Day 28 and Week 12 for the first flare and subsequent flares treated during the extension period

  16. Proportion of Patients With Anti-drug Antibodies (ADA) Against Anakinra

    Confirmed ADA positive samples will be analysed for the presence of neutralizing antibodies

    Time frame: Baseline (predose) and at 72 hours, Day 8, Day 15, Day 28 and Week 12 for the first flare and subsequent flares treated treated during the extension period

  17. Proportion of Patients With Neutralizing Antibodies

    Confirmed ADA positive samples will be analysed for the presence of neutralizing antibodies

    Time frame: Baseline (predose) and at 72 hours, Day 8, Day 15, Day 28 and Week 12 for the first flare and subsequent flares treated during the extension period

  18. Change From Baseline in Short Form (36) Health Survey, Acute Version 2 (SF-36®) Physical Functioning Domain Score

    SF-36® measures the impact of disease on overall quality of life. It consists of 8 individual domains. Score range from 0 to 100, where 0 represents the worst possible health and 100 is perfect health.

    Time frame: at baseline, Day 8 and Day 15 for the first flare treated in the study

  19. Change From Baseline in Health Related Quality of Life EuroQol 5 Dimensions 5 Levels (EQ-5D-5L)

    Exploratory objective. The EQ-5D-5L, a self-report questionnaire, is a descriptive system of Health related quality of life (HRQL) states consisting of 5 dimensions (Mobility, Self-care, Usual activities, Pain/Discomfort, Anxiety/Depression), each of which can have 5 responses. The responses record 5 levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension.

    Time frame: at baseline, Day 8 and Day 15 for the first flare treated in the study

  20. Percent Impairment While Working During Last Week Due to Gout During the First Flare and Subsequent Flares

    The WPAI yeilds four types of scores of which Work productivity loss is one. SHP is derived from WPAI as follows: The WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity as follows: Questions: Q1 = currently employed Q2 = hours missed due to specified problem Q3 = hours missed other reasons Q4 = hours actually worked Q5 = degree problem affected productivity while working Q6 = degree problem affected regular activities Scores: Multiply scores by 100 to express in percentages. Percent impairment while working due to problem: Q5/10 The answer on Q5 is given on a scale from 0 (PROBLEM had no effect on work) to 10 (PROBLEM completely prevented me from working). Thus the analysis values from which mean and SD have been calculated and reported are the outcomes from Q5 (ranging from 0 to 10) multiplied with 100 and divided by 10.

    Time frame: Recorded up to Day 15 for the first flare and subsequent flares treated during the extension period

  21. Health Care Resource Utilization Due to a Gouty Arthritis Flare

    Exploratory objective: number of days with hospitalization and un-scheduled outpatient visits

    Time frame: Recorded up to Day 15 for the first flare and subsequent flares treated during the extension period

07

Results

Posted Jul 15, 2020

Participant flow

Participant flow — Overall Study
MilestoneTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
Started555654
Intention to treat populatio555654
Safety population545552
Completed354036
Not completed201618

Outcome measures

PrimaryChange in Patient-assessed Pain Intensity in the Index Joint From Baseline to 24-72 Hours for the First Gout Flare Treated in the Study as Measured by VAS

Patients will score their pain intensity in the joint most affected at baseline (index joint) on a 0-100 mm visual analogue scale (VAS), ranging from no pain (0) to unbearable pain (100). Average of the assessments performed at 24, 48 and 72 hours.

Time frame:
At baseline (pre-dose) and at 24, 48 and 72 hours for the first gout flare treated in the study
Reported as:
Mean · Units on a scale
Change in Patient-assessed Pain Intensity in the Index Joint From Baseline to 24-72 Hours for the First Gout Flare Treated in the Study as Measured by VAS
Units on a scaleTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
24 hours-26.1 (-32.5 to -19.6)-32.5 (-38.8 to -26.1)-31.1 (-37.6 to -24.6)
48 hours-43.4 (-50.8 to -36.0)-42.9 (-50.0 to -35.9)-43.6 (-51.0 to -36.3)
72 hours-45.2 (-52.7 to -37.7)-51.6 (-58.9 to -44.3)-49.1 (-56.5 to -41.6)
SecondaryChange in Patient-assessed Pain Intensity in the Index Joint From Baseline at Time Points From 6 Hours to 8 Days for the First Gout Flare Treated in the Study as Measured by 5-point Likert Scale

Patients will score their pain intensity in the joint most affected at baseline (index joint) on a 5-point Likert scale (0-4 point scale: "none", "mild", "moderate", "severe", "extreme") at time points baseline (pre-dose) and at 6, 12, 18, 24, 36, 48 and 72 hours and Day 5, 6, 7 and 8.

Time frame:
At baseline (pre-dose) and at 6, 12, 18, 24, 36, 48 and 72 hours and Day 5, 6, 7 and 8 for the first gout flare treated in the study
Reported as:
Mean · Score on a scale
Change in Patient-assessed Pain Intensity in the Index Joint From Baseline at Time Points From 6 Hours to 8 Days for the First Gout Flare Treated in the Study as Measured by 5-point Likert Scale
Score on a scaleTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
6 hours-0.6 ± 0.7-0.8 ± 0.9-0.4 ± 0.8
12 hours-0.9 ± 0.6-1.1 ± 1.2-0.5 ± 0.7
18 hours-0.8 ± 0.8-1.2 ± 1.0-0.8 ± 0.9
24 hours-1.0 ± 0.8-0.9 ± 1.0-1.1 ± 0.9
36 hours-1.3 ± 0.8-1.3 ± 1.0-1.1 ± 0.7
48 hours-1.5 ± 1.0-1.4 ± 1.0-1.5 ± 1.0
72 hours-1.6 ± 1.1-1.6 ± 1.0-1.7 ± 0.9
Day 5-1.8 ± 1.1-1.8 ± 1.1-1.8 ± 1.1
Day 6-1.9 ± 1.1-2.2 ± 1.1-1.9 ± 1.0
Day 7-2.4 ± 0.8-2.2 ± 1.1-1.9 ± 1.0
Day 8-1.9 ± 0.9-2.1 ± 1.1-2.1 ± 1.0
SecondaryMedian Time to Onset of Effect

Onset of effect defined as 20% change from baseline pain intensity in the index joint on a visual analogue scale (VAS)

Time frame:
From baseline (predose) up to Day15 of the first flare treated in the study
Reported as:
Median · Hours
Median Time to Onset of Effect
HoursTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
Median Time to Onset of Effect22.3 (13.9 to 24.6)11.8 (7.7 to 24.0)19.8 (12.1 to 30.0)
SecondaryMedian Time to Response

Response defined as 50% change from baseline pain intensity on a visual analogue scale (VAS)

Time frame:
From baseline (predose) up to Day15 of the first flare treated in the study
Reported as:
Median · Hours
Median Time to Response
HoursTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
Median Time to Response47.6 (40.3 to 67.7)43.0 (18.6 to 70.4)46.9 (24.1 to 67.4)
SecondaryMedian Time to Resolution of Pain

Resolution of pain defined as \<10 mm on VAS, a continuous 0 to 100 mm visual analogue scale, ranging from no pain (0) to unbearable pain (100), in the index joint

Time frame:
From baseline (predose) up to Day15 of the first flare
Reported as:
Median · Hours
Median Time to Resolution of Pain
HoursTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
Median Time to Resolution of Pain167.5 (120.1 to 264.2)131.8 (70.9 to NA)119.8 (69.0 to 144.2)
SecondaryMedian Time to First Intake of Rescue Medication From First Investigational Drug Administration

Time to first intake of rescue medication for acute gout, measured in hours from first investigational drug administration

Time frame:
From Day 1 to Day 15 for the first flare treated
Reported as:
Median · Hours
Median Time to First Intake of Rescue Medication From First Investigational Drug Administration
HoursTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
Median Time to First Intake of Rescue Medication From First Investigational Drug AdministrationNA (126.5 to NA)NA (114.4 to NA)NA (220.7 to NA)
SecondaryPhysician's Assessment of Global Response to Treatment

5-point Likert scale (0- to 4-point scale: "none", "mild", "moderate", "severe, "extreme") where higher score mean worse outcome

Time frame:
At 72 hours, Day 8 and Day 15 for the first flare treated in the study
Reported as:
Mean · Score on a scale
Physician's Assessment of Global Response to Treatment
Score on a scaleTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
72 hours1.54 (1.23 to 1.85)1.25 (0.94 to 1.55)1.25 (0.94 to 1.56)
Day 81.26 (0.93 to 1.59)0.90 (0.59 to 1.20)0.81 (0.48 to 1.14)
Day 151.04 (0.69 to 1.39)0.80 (0.47 to 1.13)0.78 (0.46 to 1.13)
SecondaryPhysician's Assessment of Clinical Signs in Index Joint: Tenderness

4-point Likert scale (0=no pain, 1= mild/patient states there is pain when touched, 2= moderate/patient states there is pain and Winces, 3=severe/patient states there is pain, winces and withdraws

Time frame:
at 72 hours, Day 8 and Day 15 for the first flare treated in the study
Reported as:
Count of participants · Participants
Physician's Assessment of Clinical Signs in Index Joint: Tenderness
ParticipantsTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
72 hours : None81816
72 hours : Mild222825
72 hours : Moderate1749
72 hours : Severe431
72 hours : Missing433
Day 8 : None192830
Day 8 : Mild251917
Day 8 : Moderate421
Day 8 : Severe141
Day 8 : Missing635
Day 15 : None373832
Day 15 : Mild10912
Day 15 : Moderate155
Day 15 : Severe110
Day 15 : Missing635
SecondaryPhysician's Assessment of Clinical Signs in Index Joint: Swelling

4-point Likert scale (0=no swelling, 1= mild swelling, 2=moderate swelling, 3=severe swelling or bulging beyond joint margins)

Time frame:
at 72 hours, Day 8 and Day 15 for the first flare treated in the study
Reported as:
Count of participants · Participants
Physician's Assessment of Clinical Signs in Index Joint: Swelling
ParticipantsTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
Baseline : None000
Baseline : Mild9147
Baseline : Moderate232728
Baseline : Severe231518
Baseline : Missing001
72 hours : None142717
72 hours : Mild221826
72 hours : Moderate1077
72 hours : Severe511
72 hours : Missing433
Day 8 : None253738
Day 8 : Mild16139
Day 8 : Moderate722
Day 8 : Severe110
Day 8 : Missing635
Day 15 : None374434
Day 15 : Mild9614
Day 15 : Moderate231
Day 15 : Severe100
Day 15 : Missing635
SecondaryPhysician's Assessment of Clinical Signs in Index Joint: Erythema

Physicians assessment of clinical signs with 2 outcomes: Absent=no erythema, present=erythema

Time frame:
at 72 hours, Day 8 and Day 15 for the first flare treated in the study
Reported as:
Count of participants · Participants
Physician's Assessment of Clinical Signs in Index Joint: Erythema
ParticipantsTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
Baseline : Absent388
Baseline : Present514845
Baseline : Missing101
72 hours : Absent293937
72 hours : Present221414
72 hours : Missing433
Day 8 : Absent434340
Day 8 : Present699
Day 8 : Missing645
Day 15 : Absent474740
Day 15 : Present259
Day 15 : Missing645
SecondaryPatient´s Assessment of Global Response to Treatment (5-point Likert Scale)

5-point Likert scale (0- to 4-point scale: 0=excellent, 1=very good, 2=good, 3=fair, 4=poor response to treatment) where lower rate indicates better response to treatment

Time frame:
at 72 hours, Day 8 and Day 15 for the first flare treated in the study
Reported as:
Count of participants · Participants
Patient´s Assessment of Global Response to Treatment (5-point Likert Scale)
ParticipantsTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
72 hours : Excellent111018
72 hours : Very good13199
72 hours : Good71415
72 hours : Fair743
72 hours : Poor411
72 hours : Missing1388
Day 8 : Excellent91619
Day 8 : Very good162113
Day 8 : Good867
Day 8 : Fair562
Day 8 : Poor501
Day 8 : Missing12712
Day 15 : Excellent141921
Day 15 : Very good91311
Day 15 : Good10810
Day 15 : Fair653
Day 15 : Poor301
Day 15 : Missing13118
SecondaryChange From Baseline in the Inflammatory Biomarker C Reactive Protein

This endpoint represents the change from baseline, mg/dL, of the inflammatory biomarker C reactive protein

Time frame:
baseline (predose) and at 72 hours, Day 8 and Day 15 for the first flare treated in the study
Reported as:
Mean · mg/dL
Change From Baseline in the Inflammatory Biomarker C Reactive Protein
mg/dLTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
72 hours-0.362 ± 3.435-1.435 ± 2.057-1.362 ± 1.682
Day 8-0.321 ± 2.153-1.334 ± 2.7021.406 ± 1.961
Day 15-1.102 ± 1.690-0.724 ± 2.525-0.607 ± 2.646
SecondaryChange From Baseline in the Inflammatory Biomarker Serum Amyloid A

This endpoint represents the change from baseline, mg/L, of the inflammatory biomarker Serum amyloid A

Time frame:
baseline (predose) and at 72 hours, Day 8 and Day 15 for the first flare treated in the study
Reported as:
Mean · mg/L
Change From Baseline in the Inflammatory Biomarker Serum Amyloid A
mg/LTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
72 hours8.950 ± 246.317-45.160 ± 126.986-34.510 ± 58.518
Day 8-6.363 ± 117.794-46.561 ± 144.630-35.887 ± 64.144
Day 15-50.524 ± 105.170-25.328 ± 144.03914.370 ± 146.627
SecondaryThe Percent of Patients With at Least One Adverse Event

All adverse events to be recorded Day 1 - Day 28 for each flare. Serious adverse events (SAE) will be collected from informed consent until week 12 for each flare. Any SAE with suspected causal relationship should be reported irrespective of the time of occurrence.

Time frame:
Through study completion, at 12 weeks after last flare treated during the extension period
Reported as:
Number · Percent
The Percent of Patients With at Least One Adverse Event
PercentTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
The Percent of Patients With at Least One Adverse Event40.738.255.8
SecondaryThe Percent of Patients With at Least One Serious Adverse Event, Including Death

Serious Adverse Events (SAE) will be collected from informed consent until week 12 for each flare. Any SAE with suspected causal relationship should be reported irrespective of the time of occurrence.

Time frame:
Through study completion, at 12 weeks after last flare treated during the extension period
Reported as:
Number · Percent
The Percent of Patients With at Least One Serious Adverse Event, Including Death
PercentTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
The Percent of Patients With at Least One Serious Adverse Event, Including Death07.30
SecondarySerum Concentration of Endogenous Interleukin-1 Receptor Antagonist /Anakinra

This endpoint represents the level of of endogenous interleukin-1 receptor antagonist /anakinra

Time frame:
Baseline (predose) and at 72 hours, Day 8, Day 15, Day 28 and Week 12 for the first flare and subsequent flares treated during the extension period
Reported as:
Mean · ng/mL
Serum Concentration of Endogenous Interleukin-1 Receptor Antagonist /Anakinra
ng/mLTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
First flare : Baseline2.032 ± 2.4934.883 ± 24.3781.950 ± 2.755
First flare : 72 hours1.974 ± 1.793267.744 ± 246.086628.053 ± 540.488
First flare : Day 81.692 ± 1.3436.750 ± 10.43934.777 ± 87.812
First flare : Day 151.533 ± 0.2261.588 ± 0.4431.574 ± 0.356
First flare : Day 281.635 ± 0.6151.659 ± 1.0571.779 ± 0.895
First flare : Week 121.500 ± 0.0001.625 ± 0.4781.719 ± 0.681
Second flare : Baseline1.748 ± 1.0241.718 ± 0.7321.500 ± 0.00
Second flare : 72 hours1.628 ± 0.526254.930 ± 249.962719.667 ± 840.530
Second flare : Day 83.141 ± 6.2707.048 ± 20.33848.785 ± 114.114
Second flare : Day 151.845 ± 12911.595 ± 0.4571.500 ± 0.00
Second flare : Day 281.975 ± 1.7141.692 ± 0.8821.500 ± 0.00
Second flare : Week 122.920 ± 4.4901.681 ± 0.7251.692 ± 0.636
Third flare : Baseline2.05 ± 1.241.50 ± 0.001.50 ± 0.00
Third flare : 72 hours1.85 ± 0.78196.67 ± 192.56431.63 ± 298.51
Third flare : Day 81.50 ± 0.005.56 ± 12.9710.70 ± 15.42
Third flare : Day 151.50 ± 0.001.63 ± 0.441.50 ± 0.00
Third flare : Day 281.85 ± 0.781.50 ± 0.002.47 ± 2.38
Third flare : Week 122.85 ± 1.911.50 ± 0.001.50 ± 0.00
Fourth flare : Baseline1.50 ± 0.001.50 ± 0.001.50 ± 0.00
Fourth flare : 72 hours1.50 ± 0.00184.40 ± 198.19916.62 ± 1549.55
Fourth flare : Day 81.50 ± 0.001.89 ± 1.0220.62 ± 34.10
Fourth flare : Day 151.50 ± 0.001.50 ± 0.001.50 ± 0.00
Fourth flare : Day 281.50 ± 0.001.50 ± 0.001.50 ± 0.00
Fourth flare : Week 121.50 ± 0.002.66 ± 2.601.50 ± 0.00
Fifth flare : Baseline1.50 ± 0.001.50 ± 0.001.50 ± 0.00
Fifthe flare : 72 hours1.50 ± 0.00129.20 ± 200.26292.35 ± 308.56
Fifthe flare : Day 81.50 ± 0.001.50 ± 0.006.39 ± 9.49
Fifthe flare : Day 151.50 ± 0.001.50 ± 0.001.50 ± 0.00
Fifthe flare : Day 281.50 ± 0.003.31 ± 2.551.50 ± 0.00
Fifth flare : Week 121.50 ± 0.00—1.50 ± 0.00
SecondaryProportion of Patients With Anti-drug Antibodies (ADA) Against Anakinra

Confirmed ADA positive samples will be analysed for the presence of neutralizing antibodies

Time frame:
Baseline (predose) and at 72 hours, Day 8, Day 15, Day 28 and Week 12 for the first flare and subsequent flares treated treated during the extension period
Reported as:
Number · participants
Proportion of Patients With Anti-drug Antibodies (ADA) Against Anakinra
participantsTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
First flare : Baseline252
First flare : Day 8143
First flare : Day 15054
First flare : Day 28042
First flare : Week 12040
Second flare : Baseline002
Second flare : Day 8012
Second flare : Day 15010
Second flare : Day 28011
Second flare : Week 12001
Third flare : Baseline002
Third flare : Day 8014
Third flare : Day 15014
Third flare : Day 28010
Third flare : Week 12000
Fourth flare : Baseline002
Fourth flare : Day 8013
Fourth flare : Day 15014
Fourth flare : Day 28011
Fourth flare : Week 12010
Fifth flare : Baseline001
Fifth flare : Day 8012
Fifth flare : Day 15022
Fifth flare : Day 28012
Fifth flare : Week 12000
SecondaryProportion of Patients With Neutralizing Antibodies

Confirmed ADA positive samples will be analysed for the presence of neutralizing antibodies

Time frame:
Baseline (predose) and at 72 hours, Day 8, Day 15, Day 28 and Week 12 for the first flare and subsequent flares treated during the extension period
Reported as:
Number · participants
Proportion of Patients With Neutralizing Antibodies
participantsTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
First flare : Baseline000
First flare : Day 8000
First flare : Day 15000
First flare : Day 28000
First flare : Week 12000
Second flare : Study baseline000
Second flare : Flare baseline000
Second flare : Day 8000
Second flare : Day 15000
Second flare : Day 28000
Second flare : Week 12000
Third flare : Study baseline000
Third flare : Flare baseline000
Third flare : Day 8000
Third flare : Day 15000
Third flare : Day 28000
Third flare : Week 12000
Fourth flare : Study baseline000
Fourth flare : Flare baseline000
Fourth flare : Day 8010
Fourth flare : Day 15001
Fourth flare : Day 28000
Fourth flare : Week 12000
Fifth flare : Study baseline000
Fifth flare : Flare baseline000
Fifth flare : Day 8000
Fifth flare : Day 15000
Fifth flare : Day 28000
Fifth flare : Week 12000
SecondaryChange From Baseline in Short Form (36) Health Survey, Acute Version 2 (SF-36®) Physical Functioning Domain Score

SF-36® measures the impact of disease on overall quality of life. It consists of 8 individual domains. Score range from 0 to 100, where 0 represents the worst possible health and 100 is perfect health.

Time frame:
at baseline, Day 8 and Day 15 for the first flare treated in the study
Reported as:
Mean · units on a scale
Change From Baseline in Short Form (36) Health Survey, Acute Version 2 (SF-36®) Physical Functioning Domain Score
units on a scaleTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
Day 88.0 ± 9.810.5 ± 10.010.4 ± 8.3
Day 1511.8 ± 8.212.2 ± 11.99.4 ± 8.7
SecondaryChange From Baseline in Health Related Quality of Life EuroQol 5 Dimensions 5 Levels (EQ-5D-5L)

Exploratory objective. The EQ-5D-5L, a self-report questionnaire, is a descriptive system of Health related quality of life (HRQL) states consisting of 5 dimensions (Mobility, Self-care, Usual activities, Pain/Discomfort, Anxiety/Depression), each of which can have 5 responses. The responses record 5 levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension.

Time frame:
at baseline, Day 8 and Day 15 for the first flare treated in the study
Reported as:
Count of participants · Participants
Change From Baseline in Health Related Quality of Life EuroQol 5 Dimensions 5 Levels (EQ-5D-5L)
ParticipantsTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
Mobility scores : Day 8 — Improvement 4 step210
Mobility scores : Day 8 — Improvement 3 step565
Mobility scores : Day 8 — Improvement 2 step12911
Mobility scores : Day 8 — Improvement 1 step51812
Mobility scores : Day 8 — No change1479
Mobility scores : Day 8 — Deterioration 1 steps332
Mobility scores : Day 8 — Deterioration 2 steps030
Mobility scores : Day 8 — Deterioration 3 steps000
Mobility scores : Day 8 — Detorioration 4 steps000
Mobility scores : Day 8 — Missing14915
Mobility scores : Day 15 — Improvement 4 step210
Mobility scores : Day 15 — Improvement 3 step772
Mobility scores : Day 15 — Improvement 2 step111015
Mobility scores : Day 15 — Improvement 1 step81610
Mobility scores : Day 15 — No change9514
Mobility scores : Day 15 — Deterioration 1 steps142
Mobility scores : Day 15 — Deterioration 2 steps010
Mobility scores : Day 15 — Deterioration 3 steps000
Mobility scores : Day 15 — Detorioration 4 steps000
Mobility scores : Day 15 — Missing171211
Self-care scores : Day 8 — Improvement 4 step210
Self-care scores : Day 8 — Improvement 3 step333
Self-care scores : Day 8 — Improvement 2 step437
Self-care scores : Day 8 — Improvement 1 step7116
Self-care scores : Day 8 — No change232722
Self-care scores : Day 8 — Deterioration 1 steps111
Self-care scores : Day 8 — Deterioration 2 steps110
Self-care scores : Day 8 — Deterioration 3 steps000
Self-care scores : Day 8 — Detorioration 4 steps000
Self-care scores : Day 8 — Missing14915
Selfcare scores : Day 15 — Improvement 4 step210
Selfcare scores : Day 15 — Improvement 3 step231
Selfcare scores : Day 15 — Improvement 2 step557
Selfcare scores : Day 15 — Improvement 1 step81010
Selfcare scores : Day 15 — No change202125
Selfcare scores : Day 15 — Deterioration 1 steps130
Selfcare scores : Day 15 — Deterioration 2 steps010
Selfcare scores : Day 15 — Deterioration 3 steps000
Selfcare scores : Day 15 — Detorioration 4 steps000
Selfcare scores : Day 15 — Missing171211
Usual activities scores : Day 8 — Improvement 4 step300
Usual activities scores : Day 8 — Improvement 3 step362
Usual activities scores : Day 8 — Improvement 2 step151113
Usual activities scores : Day 8 — Improvement 1 step10149
Usual activities scores : Day 8 — No change61214
Usual activities scores : Day 8 — Deterioration 1 steps421
Usual activities scores : Day 8 — Deterioration 2 steps020
Usual activities scores : Day 8 — Deterioration 3 steps000
Usual activities scores : Day 8 — Detorioration 4 steps000
Usual activities scores : Day 8 — Missing14915
Usual activities scores : Day 15 — Improvement 4 step210
Usual activities scores : Day 15 — Improvement 3 step870
Usual activities scores : Day 15 — Improvement 2 step101113
Usual activities scores : Day 15 — Improvement 1 step101213
Usual activities scores : Day 15 — No change6914
Usual activities scores : Day 15 — Deterioration 1 steps232
Usual activities scores : Day 15 — Deterioration 2 steps011
Usual activities scores : Day 15 — Deterioration 3 steps000
Usual activities scores : Day 15 — Detorioration 4 steps000
Usual activities scores : Day 15 — Missing171211
Pain/discomfort scores : Day 8 — Improvement 4 step330
Pain/discomfort scores : Day 8 — Improvement 3 step51111
Pain/discomfort scores : Day 8 — Improvement 2 step161215
Pain/discomfort scores : Day 8 — Improvement 1 step12159
Pain/discomfort scores : Day 8 — No change444
Pain/discomfort scores : Day 8 — Deterioration 1 steps010
Pain/discomfort scores : Day 8 — Deterioration 2 steps110
Pain/discomfort scores : Day 8 — Deterioration 3 steps000
Pain/discomfort scores : Day 8 — Detorioration 4 steps000
Pain/discomfort scores : Day 8 — Missing14915
Pain/discomfort scores : Day 15 — Improvement 4 step331
Pain/discomfort scores : Day 15 — Improvement 3 step91110
Pain/discomfort scores : Day 15 — Improvement 2 step171314
Pain/discomfort scores : Day 15 — Improvement 1 step51110
Pain/discomfort scores : Day 15 — No change328
Pain/discomfort scores : Day 15 — Deterioration 1 steps130
Pain/discomfort scores : Day 15 — Deterioration 2 steps010
Pain/discomfort scores : Day 15 — Deterioration 3 steps000
Pain/discomfort scores : Day 15 — Detorioration 4 steps000
Pain/discomfort scores : Day 15 — Missing171211
Anxiety/depression scores : Day 8 — Improvement 4 step100
Anxiety/depression scores : Day 8 — Improvement 3 step220
Anxiety/depression scores : Day 8 — Improvement 2 step303
Anxiety/depression scores : Day 8 — Improvement 1 step599
Anxiety/depression scores : Day 8 — No change263325
Anxiety/depression scores : Day 8 — Deterioration 1 steps432
Anxiety/depression scores : Day 8 — Deterioration 2 steps000
Anxiety/depression scores : Day 8 — Deterioration 3 steps000
Anxiety/depression scores : Day 8 — Detorioration 4 steps000
Anxiety/depression scores : Day 8 — Missing14915
Anxiety/depression scores : Day 15 — Improvement 4 step100
Anxiety/depression scores : Day 15 — Improvement 3 step120
Anxiety/depression scores : Day 15 — Improvement 2 step413
Anxiety/depression scores : Day 15 — Improvement 1 step7610
Anxiety/depression scores : Day 15 — No change233326
Anxiety/depression scores : Day 15 — Deterioration 1 steps024
Anxiety/depression scores : Day 15 — Deterioration 2 steps200
Anxiety/depression scores : Day 15 — Deterioration 3 steps000
Anxiety/depression scores : Day 15 — Detorioration 4 steps000
Anxiety/depression scores : Day 15 — Missing171211
SecondaryPercent Impairment While Working During Last Week Due to Gout During the First Flare and Subsequent Flares

The WPAI yeilds four types of scores of which Work productivity loss is one. SHP is derived from WPAI as follows: The WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity as follows: Questions: Q1 = currently employed Q2 = hours missed due to specified problem Q3 = hours missed other reasons Q4 = hours actually worked Q5 = degree problem affected productivity while working Q6 = degree problem affected regular activities Scores: Multiply scores by 100 to express in percentages. Percent impairment while working due to problem: Q5/10 The answer on Q5 is given on a scale from 0 (PROBLEM had no effect on work) to 10 (PROBLEM completely prevented me from working). Thus the analysis values from which mean and SD have been calculated and reported are the outcomes from Q5 (ranging from 0 to 10) multiplied with 100 and divided by 10.

Time frame:
Recorded up to Day 15 for the first flare and subsequent flares treated during the extension period
Reported as:
Mean · percent
Percent Impairment While Working During Last Week Due to Gout During the First Flare and Subsequent Flares
percentTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
First flare : Day 836.1 ± 34.332.6 ± 29.120.5 ± 25.0
First flare : Day 1523.3 ± 24.812.6 ± 20.721.6 ± 22.3
Second flare : Day 842.9 ± 27.524.0 ± 26.324.0 ± 27.2
Second flare : Day 1516.0 ± 25.120.0 ± 17.613.8 ± 16.9
Third flare : Day 810.05.0 ± 7.110.0 ± 10.0
Third flare : Day 1510.020.0 ± 24.523.3 ± 32.1
Fourth flare : Day 830.0—20.0 ± 34.6
Fourth flare : Day 15——5.0 ± 7.1
Fifth flare : Day 860.0—26.7 ± 25.2
Fifth flare : Day 1520.040.013.3 ± 11.5
SecondaryHealth Care Resource Utilization Due to a Gouty Arthritis Flare

Exploratory objective: number of days with hospitalization and un-scheduled outpatient visits

Time frame:
Recorded up to Day 15 for the first flare and subsequent flares treated during the extension period
Reported as:
Mean · days
Health Care Resource Utilization Due to a Gouty Arthritis Flare
daysTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
Hospitalization : First flare : Day 1-70 ± 00 ± 00 ± 0
Hospitalization : First flare : Day 8-150 ± 00 ± 00 ± 0
Hospitalization : First flare : Day 1-150 ± 00 ± 00 ± 0
Hospitalization : Second flare : Day 1-70 ± 00 ± 00 ± 0
Hospitalization : Second flare : Day 8-150 ± 00 ± 00 ± 0
Hospitalization : Second flare : Day 1-150 ± 00 ± 00 ± 0
Hospitalization : Third flare : Day 1-70 ± 00 ± 00 ± 0
Hospitalization : Third flare : Day 8-150 ± 00 ± 00 ± 0
Hospitalization : Third flare : Day 1-150 ± 00 ± 00 ± 0
Hospitalization : Fourth flare : Day 1-70 ± 00 ± 00 ± 0
Hospitalization : Fourth flare : Day 8-150 ± 00 ± 00 ± 0
Hospitalization : Fourth flare : Day 1-150 ± 00 ± 00 ± 0
Hospitalization : Fifth flare : Day 1-70 ± 00 ± 00 ± 0
Hospitalization : Fifth flare : Day 8-150 ± 00 ± 00 ± 0
Hospitalization : Fifth flare : Day 1-150 ± 00 ± 00 ± 0
Unscheduled outpatient visits:First flare: Day 1-70.1 ± 0.50 ± 00.1 ± 0.6
Unscheduled outpatient visits:First flare:Day 8-150.3 ± 1.40.1 ± 0.60 ± 0
Unscheduled outpatient visits:First flare:Day 1-150.4 ± 1.40.1 ± 0.60.1 ± 0.6
Unscheduled outpatient visits:Second flare:Day 1-70.2 ± 0.80 ± 00 ± 0
Unscheduled outpatient visit:Second flare:Day 8-150.2 ± 0.60 ± 00 ± 0
Unscheduled outpatient visit:Second flare:Day 1-150.5 ± 1.50 ± 00 ± 0
Unscheduled outpatient visits:Third flare:Day 1-70.4 ± 0.90 ± 00 ± 0
Unscheduled outpatient visits:Third flare:Day 8-150.4 ± 0.90 ± 00 ± 0
Unscheduled outpatient visits:Third flare:Day 1-150.8 ± 1.80 ± 00 ± 0
Unscheduled outpatient visitstFourth flare:Day 1-70 ± 00 ± 00 ± 0
Unscheduled outpatient visitsFourth flare:Day 8-150 ± 00 ± 00 ± 0
Unscheduled outpatient visitsFourth flare:Day 1-150 ± 00 ± 00 ± 0
Unscheduled outpatient visit:Fifth flare : Day 1-70 ± 00 ± 00 ± 0
Unscheduled outpatient visitFifth flare : Day 8-150 ± 00 ± 00 ± 0
Unscheduled outpatient visit Fifth flare:Day 1-150 ± 00 ± 00 ± 0

Adverse events

Collected over The period for recording all adverse events, including SAEs begins upon receiving the first dose of Investigational medicinal product (IMP) and ends with a follow-up telephone call 5 weeks after the first dose of IMP. SAEs will also be collected from signing of the Informed consent form (ICF) until the Week 12 visit. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Triamcinolone 40 mg0/54 (0%)0/54 (0%)22/54 (40.7%)
Anakinra 100 mg0/55 (0%)4/55 (7.3%)19/55 (34.5%)
Anakinra 200 mg0/52 (0%)1/52 (1.9%)29/52 (55.8%)
Most frequent serious events
Most frequent serious events
EventTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
Coronary artery diseaseCardiac disorders0/541/551/52
AnaemiaBlood and lymphatic system disorders0/541/550/52
SeizureNervous system disorders0/541/550/52
Gastric ulcerGastrointestinal disorders0/541/550/52
Sickel cell anaemiaCongenital, familial and genetic disorders0/541/550/52
Most frequent other events
Showing 10 of 107
Most frequent other events
EventTriamcinolone 40 mgAnakinra 100 mgAnakinra 200 mg
InfluenzaInfections and infestations0/543/555/52
Blood triglycerides increasedInvestigations1/540/555/52
NeutropeniaBlood and lymphatic system disorders0/541/553/52
HypertriglyceridaemiaMetabolism and nutrition disorders0/543/552/52
HeadacheNervous system disorders2/540/552/52
ArthralgiaMusculoskeletal and connective tissue disorders1/542/552/52
MicroalbuminuriaRenal and urinary disorders0/540/552/52
Oedema peripheralGeneral disorders0/541/552/52
Injection site hypersensitivityGeneral disorders0/540/552/52
Ligament sprainInjury, poisoning and procedural complications1/540/552/52

Baseline characteristics

Age, Continuous
Age, Continuous(years)Triamcinolone 40 mgAnakinra 100 mgAnakinra 200 mgTotal
Mean56.8 ± 10.353.7 ± 11.954.0 ± 13.154.8 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Triamcinolone 40 mgAnakinra 100 mgAnakinra 200 mgTotal
Female78722
Male484847143
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Triamcinolone 40 mgAnakinra 100 mgAnakinra 200 mgTotal
Race — White393842119
Race — Black or African American15151242
Race — Asian1304
Region of Enrollment
Region of Enrollment(participants)Triamcinolone 40 mgAnakinra 100 mgAnakinra 200 mgTotal
United States555654165
08

Study locations

37 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Fundamental Research, LLC
    Gulf Shores, Alabama 36542, United States
  • Coastal Clinical Research, Inc
    Mobile, Alabama 36608, United States
  • Advanced Research Center
    Anaheim, California 92805, United States
  • Delta Waves Sleep Disorder and Research Center
    Colorado Springs, Colorado 80918, United States
  • Pulmonary Associates of Brandon
    Brandon, Florida 33511, United States
  • Meridien Research
    Brooksville, Florida 34601, United States
  • Health Awareness
    Jupiter, Florida 33458, United States
  • Well Pharma Medical Research
    Miami, Florida 33143, United States
  • Clinical Neuroscience Solutions
    Orlando, Florida 32801, United States
  • Clinical Research Trials of Florida
    Tampa, Florida 33607, United States
  • Meridien Research, Inc
    Tampa, Florida 33634, United States
  • Kaushik Amin MD
    Conyers, Georgia 30013, United States
  • Alta Pharmaceutical Research Center
    Dunwoody, Georgia 30338, United States
  • Lemah Creek Clinical Research
    Melrose Park, Illinois 60160, United States
  • The Research Group of Lexington
    Lexington, Kentucky 40503, United States
  • Clinical Trials Management
    Metairie, Louisiana 70006, United States
  • University of Michigan
    Ann Arbor, Michigan 48109-5422, United States
  • Albuquerque Clinical Trials
    Albuquerque, New Mexico 87102, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Boiling Springs Medical Research, Inc.
    Shelby, North Carolina 28150, United States
  • PMG Research of Winston-Salem
    Winston-Salem, North Carolina 27103, United States
  • Hightop Medical Research Center
    Cincinnati, Ohio 45224, United States
  • New Horizons Clinical Research
    Cincinnati, Ohio 45242, United States
  • Clinical Research Solutions - Franklin
    Franklin, Tennessee 37067, United States
  • Clinical Research Solutions
    Smyrna, Tennessee 37167, United States
  • Renaissance Clinical Research and Hypertension Clinic of Texas, PLLC
    Dallas, Texas 75234, United States
  • Pioneer Research Solutions, Inc.
    Houston, Texas 77099, United States
  • Accurate Clinical Management
    Pasadena, Texas 77505, United States
  • Sun Research Institute
    San Antonio, Texas 78215, United States
  • Wade Family Medicine
    Bountiful, Utah 84010, United States
  • Ericksen Research & Development
    Clinton, Utah 84015, United States
  • Advanced Clinical Research - West Jordan
    West Jordan, Utah 84088, United States
  • Commonwealth Clinical Research Specialists, Inc.
    Richmond, Virginia 23235, United States
  • Corporation Lane Internal Medicine and Research Center
    Virginia Beach, Virginia 23462, United States
  • Mileground Physicians, PLLC
    Morgantown, West Virginia 26505, United States
  • Clinical Investigations Specialists, Inc.
    Kenosha, Wisconsin 53142, United States
09

References and documents

Publications

  • Saag KG, Khanna PP, Keenan RT, Ohlman S, Osterling Koskinen L, Sparve E, Akerblad AC, Wiken M, So A, Pillinger MH, Terkeltaub R. A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares. Arthritis Rheumatol. 2021 Aug;73(8):1533-1542. doi: 10.1002/art.41699. Epub 2021 Jul 7. PubMed 33605029 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Jun 2018, 18 months.

Results were first posted in Jul 2020, 2 years 1 month after primary completion. A results delay was requested in Jun 2018.

Of 25 industry-sponsored phase 2 interventional studies under Gout, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 19. This study's 18 months is above that.

Counting every sponsor, half of 30 studies reached it within 14 months; a quarter within 7 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2016
First posted
Dec 26, 2016
StartActual
Dec 2016
Primary completionActual
Jun 2018
CompletionActual
Aug 2019
Results delay requested
Jun 28, 2018
Results first posted
Jul 15, 2020
Last update
Jul 15, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03002974
Responsible party
Sponsor
First posted
Dec 26, 2016
Start date
Dec 2016
Primary completion
Jun 2018
Completion
Aug 2019
Results posted
Jul 15, 2020
Last update
Jul 15, 2020

Study contacts

Sven Ohlman, MD, PhD
study director · Swedish Orphan Biovitrum AB

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interleukin 1 Receptor Antagonist Protein

Start the discussion